大额BD+技术进步催化，生物医药ETF（512290）收涨超1%，近20日资金净流入超5亿元

Core Insights - The biopharmaceutical ETF (512290) rose over 1% on February 10, with a net inflow of over 500 million yuan in the past 20 days, driven by significant BD and technological advancements [1] Industry Summary - The 2026 JPM Healthcare Conference showcased numerous Chinese pharmaceutical companies presenting their latest research achievements and progress, alongside a surge in large BD deals and active collaborations with multinational corporations (MNCs) [1] - The development of brain-computer interfaces and AI applications is thriving, with consumer-oriented stocks expected to benefit from domestic demand recovery [1] - The industry faces several risks, including geopolitical risks overseas, potential product development failures, increased pricing pressure from expanded centralized procurement, intense competition leading to price declines, and significant rises in raw material costs [1] - The biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services from the Shanghai and Shenzhen markets to reflect the overall performance of related securities [1]